The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis
Emotionally labile, depressed participants with multiple sclerosis treated with escitalopram will have a greater reduction in emotional lability scores and in their psychological distress scores than those who are randomized to receive placebo.
Drug: escitalopram oxalate antidepressant
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Double-Blind, Placebo-Controlled Investigation Into the Safety and Efficacy of Escitalopram for Depression in Multiple Sclerosis|
- Escitalopram-treated MS patients will have greater reductions in their depressive symptom scores than patients randomized to placebo
- Adverse events for both groups will be similar
- Escitalopram-treated emotionally labile patients with MS will have a greater reduction in emotional lability scores than those randomized to placebo.
|Study Start Date:||November 2004|
|Estimated Study Completion Date:||October 2006|
Patients with multiple sclerosis who are experiencing mood lability and symptoms of depression will be randomized to receive either escitalopram 10mg/day or placebo tablets for a period of 6 weeks. It is hypothesized that patients receiving medication will experience a greater normalization of their emotional instability and a greater reduction in their depressive symptoms at the end of the six-week trial than those who are not receiving medication.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00151294
|United States, New York|
|NewYork Presbyterian Hospital|
|White Plains, New York, United States, 10605|
|Principal Investigator:||Barnett S Meyers, MD||Weill Medical College of Cornell University|